Clinical Trial Update: CREATE: Cross-tumoral Phase 2 With Crizotinib [Phase 2]

View source ↗

Summary

Phase 2 cross-tumor trial evaluating crizotinib in multiple locally advanced or metastatic cancers; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Rhabdomyosarcoma
• Alveolar Soft Part Sarcoma
• Anaplastic Large Cell Lymphoma
• Clear Cell Sarcoma
• Inflammatory Myofibroblastic Tumor
• Papillary Renal Cell Carcinoma

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Phase 2 | Status: COMPLETED